User menu

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Bibliographic reference Lamarca, Angela ; Barriuso, Jorge ; Kulke, Matthew ; Borbath, Ivan ; Lenz, Heinz-Josef ; et. al. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.. In: The British journal of cancer, Vol. 118, p. 181-188 (2018)
Permanent URL
  1. Chen H. X., Rubinstein L. V., Shankar L. K., Abrams J. S., Are We Ready for the 10% Solution?, 10.1634/theoncologist.2014-0126
  2. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  3. Faivre Sandrine, Ronot Maxime, Dreyer Chantal, Serrate Camille, Hentic Olivia, Bouattour Mohamed, Bruno Onorina, Couvelard Anne, Vilgrain Valérie, Raymond Eric, Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib, 10.1007/s11523-012-0216-y
  4. Houk Brett E., Bello Carlo L., Poland Bill, Rosen Lee S., Demetri George D., Motzer Robert J., Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis, 10.1007/s00280-009-1170-y
  5. Krajewski K. M., Franchetti Y., Nishino M., Fay A. P., Ramaiya N., Van den Abbeele A. D., Choueiri T. K., 10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study, 10.1634/theoncologist.2013-0391
  6. Krajewski Katherine M., Guo Mengye, Van den Abbeele Annick D., Yap Jeffrey, Ramaiya Nikhil, Jagannathan Jyothi, Heng Daniel Y.C., Atkins Michael B., McDermott David F., Schutz Fabio A.B., Pedrosa Ivan, Choueiri Toni K., Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma, 10.1016/j.eururo.2011.01.038
  7. Kulke Matthew H., Lenz Heinz-Josef, Meropol Neal J., Posey James, Ryan David P., Picus Joel, Bergsland Emily, Stuart Keith, Tye Lesley, Huang Xin, Li Jim Z., Baum Charles M., Fuchs Charles S., Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors, 10.1200/jco.2007.15.9020
  8. Ornstein Moshe C., Wood Laura, Elson Paul, Allman Kimberly, Beach Jennifer, Martin Allison, Gilligan Timothy, Garcia Jorge A., Rini Brian I., Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma, 10.1016/j.clgc.2016.08.014
  9. Patel Shreyaskumar, Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance, 10.1016/j.ctrv.2011.10.001
  10. Raymond Eric, Dahan Laetitia, Raoul Jean-Luc, Bang Yung-Jue, Borbath Ivan, Lombard-Bohas Catherine, Valle Juan, Metrakos Peter, Smith Denis, Vinik Aaron, Chen Jen-Shi, Hörsch Dieter, Hammel Pascal, Wiedenmann Bertram, Van Cutsem Eric, Patyna Shem, Lu Dongrui Ray, Blanckmeister Carolyn, Chao Richard, Ruszniewski Philippe, Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, 10.1056/nejmoa1003825
  11. Shi Hong-zhe, Tian Jun, Chen Xi, Wang Dong, Li Chang-ling, Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma, 10.1016/j.clgc.2016.05.007
  12. Sundin Anders, Rockall Andrea, Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead, 10.1159/000342270
  13. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  14. Thiam R., Fournier L. S., Trinquart L., Medioni J., Chatellier G., Balvay D., Escudier B., Dromain C., Cuenod C. A., Oudard S., Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib, 10.1093/annonc/mdp466
  15. van der Veldt A A M, Meijerink M R, van den Eertwegh A J M, Haanen J B A G, Boven E, Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib, 10.1038/sj.bjc.6605567
  16. Yao James C., Shah Manisha H., Ito Tetsuhide, Bohas Catherine Lombard, Wolin Edward M., Van Cutsem Eric, Hobday Timothy J., Okusaka Takuji, Capdevila Jaume, de Vries Elisabeth G.E., Tomassetti Paola, Pavel Marianne E., Hoosen Sakina, Haas Tomas, Lincy Jeremie, Lebwohl David, Öberg Kjell, Everolimus for Advanced Pancreatic Neuroendocrine Tumors, 10.1056/nejmoa1009290